Oxeia CEO Michael Wyand participated in OneNucleus BioWednesday Webinar: Prevention vs. Cure

Aug 11

Written By Lindsey McClelland

Lindsey McClelland

Public Service Announcement: Phase 2 clinical trial for Oxeia’s concussion drug, OXE103

One Nucleus: Dr. Michael Wyand to participate in panel